1. Home
  2. NRXP vs FLUX Comparison

NRXP vs FLUX Comparison

Compare NRXP & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRXP
  • FLUX
  • Stock Information
  • Founded
  • NRXP 2015
  • FLUX N/A
  • Country
  • NRXP United States
  • FLUX United States
  • Employees
  • NRXP N/A
  • FLUX N/A
  • Industry
  • NRXP Biotechnology: Pharmaceutical Preparations
  • FLUX Industrial Machinery/Components
  • Sector
  • NRXP Health Care
  • FLUX Miscellaneous
  • Exchange
  • NRXP Nasdaq
  • FLUX Nasdaq
  • Market Cap
  • NRXP 32.6M
  • FLUX 25.4M
  • IPO Year
  • NRXP N/A
  • FLUX N/A
  • Fundamental
  • Price
  • NRXP $3.34
  • FLUX $2.13
  • Analyst Decision
  • NRXP Strong Buy
  • FLUX Strong Buy
  • Analyst Count
  • NRXP 4
  • FLUX 2
  • Target Price
  • NRXP $28.50
  • FLUX $6.00
  • AVG Volume (30 Days)
  • NRXP 240.0K
  • FLUX 125.7K
  • Earning Date
  • NRXP 08-13-2025
  • FLUX 08-15-2025
  • Dividend Yield
  • NRXP N/A
  • FLUX N/A
  • EPS Growth
  • NRXP N/A
  • FLUX N/A
  • EPS
  • NRXP N/A
  • FLUX N/A
  • Revenue
  • NRXP N/A
  • FLUX $63,074,000.00
  • Revenue This Year
  • NRXP N/A
  • FLUX $11.10
  • Revenue Next Year
  • NRXP N/A
  • FLUX $12.66
  • P/E Ratio
  • NRXP N/A
  • FLUX N/A
  • Revenue Growth
  • NRXP N/A
  • FLUX N/A
  • 52 Week Low
  • NRXP $1.10
  • FLUX $1.15
  • 52 Week High
  • NRXP $6.01
  • FLUX $4.75
  • Technical
  • Relative Strength Index (RSI)
  • NRXP 60.08
  • FLUX 66.14
  • Support Level
  • NRXP $2.90
  • FLUX $1.36
  • Resistance Level
  • NRXP $3.53
  • FLUX $2.53
  • Average True Range (ATR)
  • NRXP 0.19
  • FLUX 0.20
  • MACD
  • NRXP -0.03
  • FLUX 0.09
  • Stochastic Oscillator
  • NRXP 84.13
  • FLUX 65.81

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

About FLUX Flux Power Holdings Inc.

Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.

Share on Social Networks: